Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of carboplatin/paclitaxel with ABT-869 versus carboplatin/paclitaxel alone in first-line advanced NSCLC
2007-007107-32Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Carboplatin + paclitaxel + ABT-869 with Carboplatin + paclitaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2008; status: completed.
02
Drugs
linifanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-007107-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007107-32.